New Legal Action Targets Disc Medicine and zSpace Over Alleged Shareholder Losses
New York, Wednesday, 29 April 2026.
Following significant investor losses, Rosen Law Firm launched legal actions against Disc Medicine and zSpace on April 28, 2026, highlighting critical ongoing concerns regarding corporate market transparency.
The Regulatory Setback for Disc Medicine
On April 28, 2026, Rosen Law Firm announced it is preparing a class action lawsuit on behalf of investors who purchased securities in Disc Medicine, Inc. (NASDAQ: IRON) [1]. This legal scrutiny stems from a significant regulatory hurdle the biopharmaceutical company encountered earlier in the year. On February 13, 2026, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter regarding Disc Medicine’s bitopertin program [1]. In its communication, the FDA explicitly stated that it could not approve the company’s New Drug Application (NDA) due to underlying uncertainties [1].